Incruse Ellipta approved in Canada

Canada has approved GSK’s Incruse Ellipta umeclidinium (UMEC) DPI for the once-daily treatment of COPD, the first approval for its UMEC monotherapy, the company said. GSK received a positive opinion from the EMA’s Committee for Medicinal Products for Human Use (CHMP) regarding its MAA for Incruse Ellipta in February 2014, and the company submitted an . . . Read more

OPKO Health acquires Inspiro Medical and its Inspiromatic DPI

US pharmaceutical company OPKO Health has announced that it will acquire Israeli device company Inspiro Medical whose only product is the Inspiromatic dry powder inhaler. In June 2013, Inspiro announced positive results from a study of the device used to deliver formoterol. OPKO CEO and Chairman Phillip Frost said, “We are pleased to add this . . . Read more

Alexza hires Winston R. Brown, Jr. as VP, Quality

Alexza Pharmaceuticals has hired Winston R. Brown, Jr. as VP, Quality, the company has announced. Brown was most recently Global Head, Quality R&D – Pharmaceuticals, Biologics, and Vision Care Devices at Alcon Research. The company has made several hires recently as it is in the process of commercializing its Adasuve inhaled loxapine for the treatment . . . Read more